The TECOS CVOT assessed the cardiovascular safety of sitagliptin in patients with type 2 diabetes and prior CV disease. This module details the results.

Rate this content
  • TECOS: trial design
  • TECOS: baseline characteristics
  • TECOS: CV disease at baseline
  • TECOS: renal function at baseline
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go